Zusammenfassung
Störungen der Gallensekretion können auf hepatozellulärer und cholangiozellulärer Ebene eine Cholestase verursachen. Die Bildung einer "toxischen Galle" als Folge einer abnormen Gallezusammensetzung kann zu einer Schädigung der Hepatozyten und vor allem der Gallengänge führen. Die kanalikuläre Phospholipid Flippase (Mdr2/MDR3) bewerkstelligt normalerweise die biliäre Exkretion von Phospholipiden welche in weiterer Folge gemischte Mizellen mit Gallensäuren und Cholesterin bilden, und dadurch das Gallengangsepithel vor der Detergenzienwirkung der potentiell toxischen Gallensäuren schützen. Mdr2 Knockout Mäuse sind nicht in der Lage Phospholipide in die Galle zu sezernieren und entwickeln eine Gallengangsschädigung mit den makroskopischen und mikroskopischen Zeichen einer sklerosierenden Cholangitis. MDR3 Mutationen können beim Menschen ein breites Spektrum hepatobiliärer Erkrankungen verursachen, welche von der progressiven familiären intrahepatischen Cholestase beim Neugeborenen über die intrahepatische Schwangerschaftscholestase, medikamentös-induzierte Cholestasen, intrahepatische Cholelithiasis bis hin zu sklerosierenden Cholangitis und biliären Zirrhose beim Erwachsenen reichen. Andere Beispiele für eine Gallengangsschädigung als Folge einer toxischen Galle sind die Cholangiopathie im Rahmen einer zystischen Fibrose, nach Litocholsäurefütterung im Mausmodell, sowie Vanishing Bile Duct Syndrome durch Medikamente und Xenobiotika. Der therapeutische Ansatz für Cholangiopathien kann auf eine Modulation der Gallezusammensetzung im Sinne einer Reduktion der Toxizität bzw. eine Protektion des Gallengangsepithels abzielen. Die Ursodeoxycholsäure (UDCA) weist einige dieser Eigenschaften auf, zeigte jedoch in der Therapie von Cholangiopathien beim Menschen nur eine limitierte klinische Effektivität. Im Gegensatz zu UDCA, unterliegt die Seitenketten verkürzte norUDCA einem cholehepatischen Shunting und induziert eine Bikarbonat-reiche Hypercholerese. Weiters hat norUDCA anti-inflammatorische, anti-fibrotische und anti-proliferative Effekte und stimuliert die Gallensäurendetoxifikation. Geplante klinische Studien werden erst zeigen müssen ob norUDCA oder andere Seitenketten-modifizierte Gallensäuren auch beim Menschen klinisch effektiv sind. Neue Therapieansätze beinhalten auch die Möglichkeit über Kernrezeptoren wie FXR und PPARα die Gallezusammensetzung und Galletoxizität zu beeinflussen.
Summary
Alterations in bile secretion at the hepatocellular and cholangiocellular levels may cause cholestasis. Formation of 'toxic bile' may be the consequence of abnormal bile composition and can result in hepatocellular and/or bile duct injury. The canalicular phospholipid flippase (Mdr2/MDR3) normally mediates biliary excretion of phospholipids, which normally form mixed micelles with bile acids and cholesterol to protect the bile duct epithelium from the detergent properties of bile acids. Mdr2 knockout mice are not capable of excreting phospholipids into bile and spontaneously develop bile duct injury with macroscopic and microscopic features closely resembling human sclerosing cholangitis. MDR3 mutations have been linked to a broad spectrum of hepatobiliary disorders in humans ranging from progressive familial intrahepatic cholestasis in neonates to intrahepatic cholestasis of pregnancy, drug-induced cholestasis, intrahepatic cholelithiasis, sclerosing cholangitis and biliary cirrhosis in adults. Other examples for bile injury due to the formation of toxic bile include the cholangiopathy seen in cystic fibrosis, after lithocholate feeding (in mice) and vanishing bile duct syndromes induced by drugs and xenobiotics. Therapeutic strategies for cholangiopathies may target bile composition/toxicity and the affected bile duct epithelium itself, and ideally should also have anti-cholestatic, anti-fibrotic and anti-neoplastic properties. Ursodeoxycholic acid (UDCA) shows some of these properties, but is of limited efficacy in the treatment of human cholangiopathies. By contrast to UDCA, its side chain-shortened homologue norUDCA undergoes cholehepatic shunting leading to a bicarbonate-rich hypercholeresis. Moreover, norUDCA has anti-inflammatory, anti-fibrotic and anti-proliferative effects, and stimulates bile acid detoxification. Upcoming clinical trials will have to demonstrate whether norUDCA or other side chain-modified bile acids are also clinically effective in humans. Finally, drugs for the treatment of cholangiopathies may target bile toxicity via nuclear receptors (FXR, PPARα) regulating biliary phospholipid and bile acid excretion.
References
Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev, 83: 633–671, 2003
Oude Elferink RP, Paulusma CC. Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein). Pflugers Arch, 453: 601–610, 2007
Oude Elferink RP, Paulusma CC, Groen AK. Hepatocanalicular transport defects: pathophysiologic mechanisms of rare diseases. Gastroenterology, 130: 908–925, 2006
Trauner M, Fickert P, Wagner M. MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. Semin Liver Dis, 27: 77–98, 2007
Hofmann AF. Bile acids as drugs: principles, mechanisms of action and formulations. Ital J Gastroenterol, 27: 106–113, 1995
Hofmann AF. The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med, 159: 2647–2658, 1999
Smit JJ, Schinkel AH, Oude Elferink RP, Groen AK, Wagenaar E, van Deemter L, Mol CA, Ottenhoff R, van der Lugt NM, van Roon MA, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell, 75: 451–462, 1993
Fickert P, Fuchsbichler A, Wagner M, Zollner G, Kaser A, Tilg H, Krause R, Lammert F, Langner C, Zatloukal K, Marschall HU, Denk H, Trauner M. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology, 127: 261–274, 2004
Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Weiglein AH, Lammert F, Marschall HU, Tsybrovskyy O, Zatloukal K, Denk H, Trauner M. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology, 123: 1238–1251, 2002
Popov Y, Patsenker E, Fickert P, Trauner M, Schuppan D. Mdr2 (Abcb4)−/− mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol, 43: 1045–1054, 2005
Mauad TH, van Nieuwkerk CM, Dingemans KP, Smit JJ, Schinkel AH, Notenboom RG, van den Bergh Weerman MA, Verkruisen RP, Groen AK, Oude Elferink RP, et al. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am J Pathol, 145: 1237–1245, 1994
Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature, 431: 461–466, 2004
Lammert F, Wang DQ, Hillebrandt S, Geier A, Fickert P, Trauner M, Matern S, Paigen B, Carey MC. Spontaneous cholecysto- and hepatolithiasis in Mdr2−/− mice: a model for low phospholipid-associated cholelithiasis. Hepatology, 39: 117–128, 2004
Katzenellenbogen M, Mizrahi L, Pappo O, Klopstock N, Olam D, Jacob-Hirsch J, Amariglio N, Rechavi G, Domany E, Galun E, Goldenberg D. Molecular mechanisms of liver carcinogenesis in the mdr2-knockout mice. Mol Cancer Res, 5: 1159–1170, 2007
Sheth S, Shea JC, Bishop MD, et al. Increased prevalence of CFTR mutations and variants and decreased chloride secretion in primary sclerosing cholangitis. Hum Genet, 113: 286–292, 2003
Blanco PG, Zaman MM, Junaidi O, et al. Induction of colitis in cftr−/− mice results in bile duct injury. Am J Physiol Gastrointest Liver Physiol, 287: G491–G496, 2004
Pall H, Zielenski J, Jonas MM, et al. Primary sclerosing cholangitis in childhood is associated with abnormalities in cystic fibrosis-mediated chloride channel function. J Pediatr, 151: 255–259, 2007
McGill JM, Williams DM, Hunt CM. Survey of cystic fibrosis transmembrane conductance regulator genotypes in primary sclerosing cholangitis. Dig Dis Sci, 41: 540–542, 1996
Girodon E, Sternberg D, Chazouilleres O, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene defects in patients with primary sclerosing cholangitis. J Hepatol, 37: 192–197, 2002
Gallegos-Orozco JF, C EY, Wang N, et al. Lack of association of common cystic fibrosis transmembrane conductance regulator gene mutations with primary sclerosing cholangitis. Am J Gastroenterol, 100: 874–878, 2005
Lazaridis KN, Strazzabosco M, LaRusso NF. The cholangiopathies: disorders of biliary epithelia. Gastroenterology, 127: 1565–1577, 2004
Durie PR, Kent G, Phillips MJ, Ackerley CA. Characteristic multiorgan pathology of cystic fibrosis in a long-living cystic fibrosis transmembrane regulator knockout murine model. Am J Pathol, 164: 1481–1493, 2004
Pall H, Zaman MM, Andersson C, Freedman SD. Decreased peroxisome proliferator activated receptor alpha is associated with bile duct injury in cystic fibrosis transmembrane conductance regulator−/− mice. J Pediatr Gastroenterol Nutr, 42: 275–281, 2006
Ollero M, Junaidi O, Zaman MM, Tzameli I, Ferrando AA, Andersson C, Blanco PG, Bialecki E, Freedman SD. Decreased expression of peroxisome proliferator activated receptor gamma in cftr−/− mice. J Cell Physiol, 200: 235–244, 2004
Fickert P, Stöger U, Fuchsbichler A, Moustafa T, Marschall HU, Weiglein AH, Tsybrovskyy O, Jaeschke H, Zatloukal K, Denk H, Trauner M. A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis. Am J Pathol, 171: 525–536, 2007
Chang ML, Yeh CT, Chang PY, Chen JC. Comparison of murine cirrhosis models induced by hepatotoxin administration and common bile duct ligation. World J Gastroenterol, 11: 4167–4172, 2005
Fickert P, Fuchsbichler A, Marschall HU, Wagner M, Zollner G, Krause R, Zatloukal K, Jaeschke H, Denk H, Trauner M. Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. Am J Pathol, 168: 410–422, 2006
Jansen PL, Sturm E. Genetic cholestasis, causes and consequences for hepatobiliary transport. Liver Int, 23: 315–322, 2003
Pauli-Magnus C, Stieger B, Meier Y, Kullak-Ublick GA, Meier PJ. Enterohepatic transport of bile salts and genetics of cholestasis. J Hepatol, 43: 342–357, 2005
Jacquemin E, De Vree JM, Cresteil D, Sokal EM, Sturm E, Dumont M, Scheffer GL, Paul M, Burdelski M, Bosma PJ, Bernard O, Hadchouel M, Elferink RP. The wide spectrum of multidrug resistance 3 deficiency: from neonatalcholestasis to cirrhosis of adulthood. Gastroenterology, 120: 1448–1458, 2001
Geuken E, Visser D, Kuipers F, Blokzijl H, Leuvenink HG, de Jong KP, Peeters PM, Jansen PL, Slooff MJ, Gouw AS, Porte RJ. Rapid increase of bile salt secretion is associated with bile duct injury after human liver transplantation. J Hepatol, 41: 1017–1025, 2004
Hoekstra H, Porte RJ, Tian Y, Jochum W, Stieger B, Moritz W, Slooff MJ, Graf R, Clavien PA. Bile salt toxicity aggravates cold ischemic injury of bile ducts after liver transplantation in Mdr2+/− mice. Hepatology, 43: 1022–1031, 2006
Pauli-Magnus C, Kerb R, Fattinger K, Lang T, Anwald B, Kullak-Ublick GA, Beuers U, Meier PJ. BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology, 39: 779–791, 2004
Melum E, Boberg KM, Franke A, Bergquist A, Hampe J, Schreiber S, Lie BA, Schrumpf E, Karlsen TH. Variation in the MDR3 gene influences disease progression in PSC patients and disease susceptibility in epistatic interaction with a polymorphism in the OST-alpha gene. Hepatology, 46: 265A, 2007
Prieto J, Qian C, Garcia N, Diez J, Medina JF. Abnormal expression of anion exchanger genes in primary biliary cirrhosis. Gastroenterology, 105: 572–578, 1993
Medina JF, Martinez A, Vazquez JJ, Prieto J. Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis. Hepatology, 25: 12–17, 1997
Prieto J, Garcia N, Marti-Climent JM, Penuelas I, Richter JA, Medina JF. Assessment of biliary bicarbonate secretion in humans by positron emission tomography. Gastroenterology, 117: 167–172, 1999
Melero S, Spirli C, Zsembery A, et al. Defective regulation of cholangiocyte Cl−/HCO3 (−) and Na−/H− exchanger activities in primary biliary cirrhosis. Hepatology, 35: 1513–1521, 2002
Vazquez JJ, Vazquez M, Idoate MA, et al. Anion exchanger immunoreactivity in human salivary glands in health and Sjogren's syndrome. Am J Pathol, 146: 1422–1432, 1995
Zollner G, Fickert P, Silbert D, et al. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol, 38: 717–727, 2003
Spirli C, Nathanson MH, Fiorotto R, et al. Proinflammatory cytokines inhibit secretion in rat bile duct epithelium. Gastroenterology, 121: 156–169, 2001
LaRusso NF, Shneider BL, Black D, Gores GJ, James SP, Doo E, Hoofnagle JH. Primary sclerosing cholangitis: summary of a workshop. Hepatology, 44: 746–764, 2006
Cullen SN, Chapman RW. The medical management of primary sclerosing cholangitis. Semin Liver Dis, 26: 52–61, 2006
Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol, 3: 318–328, 2006
Paumgartner G, Beuers U. Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease. Clin Liver Dis, 8: 67–81, 2004
Yoon YB, Hagey LR, Hofmann AF, Gurantz D, Michelotti EL, Steinbach JH. Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents. Gastroenterology, 90: 837–852, 1986
Hofmann AF, Zakko SF, Lira M, Clerici C, Hagey LR, Lambert KK, Steinbach JH, Schteingart CD, Olinga P, Groothuis GM. Novel biotransformation and physiological properties of norursodeoxycholic acid in humans. Hepatology, 42: 1391–1398, 2005
Fickert P, Wagner M, Marschall HU, Fuchsbichler A, Zollner G, Tsybrovskyy O, Zatloukal K, Liu J, Waalkes MP, Cover C, Denk H, Hofmann AF, Jaeschke H, Trauner M. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology, 130: 465–481, 2006
Bolder U, Trang NV, Hagey LR, Schteingart CD, Ton-Nu HT, Cerre C, Elferink RP, Hofmann AF. Sulindac is excreted into bile by a canalicular bile salt pump and undergoes acholehepatic circulation in rats. Gastroenterology, 117: 962–971, 1999
Leuschner M, Holtmeier J, Ackermann H, Leuschner U. The influence of sulindac on patients with primary biliary cirrhosis that responds incompletely to ursodeoxycholic acid: a pilot study. Eur J Gastroenterol Hepatol, 14: 1369–1376, 2002
Zollner G, Marschall HU, Wagner M, Trauner M. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol Pharm, 3: 231–251, 2006
Geier A, Wagner M, Dietrich CG, Trauner M. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim Biophys Acta, 1773: 283–308, 2007
Wagner M, Halilbasic E, Marschall HU, Zollner G, Fickert P, Langner C, Zatloukal K, Denk H, Trauner M. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology, 42: 420–430, 2005
Stojakovic T, Putz-Bankuti C, Fauler G, Scharnagl H, Wagner M, Stadlbauer V, Gurakuqi G, Stauber RE, März W, Trauner M. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology, 46: 776–784, 2007
Salas JT, Banales JM, Sarvide S, Recalde S, Ferrer A, Uriarte I, Oude Elferink RP, Prieto J, Medina JF. Ae2a,b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis. Gastroenterology, 134(5): 1482–1493, 2008
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Trauner, M., Fickert, P., Halilbasic, E. et al. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases. Wien Med Wochenschr 158, 542–548 (2008). https://doi.org/10.1007/s10354-008-0592-1
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10354-008-0592-1